Induced Pluripotent Stem Cell (iPS Cell) Market : Industry Analysis & Opportunities-DataM Intelligence
The Global Induced Pluripotent Stem Cell (iPS Cell) Market is expected to grow at a high CAGR of 9.1% during the forecasting period (2021-2028).
(EMAILWIRE.COM, September 01, 2021 ) Market Overview
Induced pluripotent stem cells (iPS cell), immature cell generated from an adult (mature) cell and has regained the capacity to differentiate into any cell in the body. iPSCs can be used to explore the causes of disease onset and progression, create and test new drugs and therapies, and potentially treat previously incurable diseases.
Market Dynamics
The induced pluripotent stem cell (ips cell) market growth is driven by the increasing therapeutic advancements with iPS Cell, growing mergers and acquisitions of organizations to expand their portfolio in iPSCs, Increasing research activities are the major driving factors of the market.
Strong pipeline of iPSC is expected to drive the growth of global induced pluripotent stem cell (ips cell) market during the forecasting period.
The prevalence of chronic diseases worldwide is driving many vendors in the market to develop novel induced pluripotent stem cell therapies. Several drugs are in the late stages of clinical trials and are expected to receive marketing approvals over the forecast period. For instance, I Peace Inc. and Avery Therapeutics are collaborating to advance an iPSC-derived cell therapy for heart failure. I Peace is generating the GMP-grade iPSCs, while Avery Therapeutics is using them to manufacture its MyCardia. I Peace can mass production clinical-grade iPSC lines simultaneously in a single room using a miniaturized plate and robotic technology. Its facility is equipped with the fully-closed automated iPSC manufacturing system that meets the safety standards of the U.S. FDA and Japanese PMDA.
Hopstem Biotechnology is one of China's first iPSC cell therapy companies and a market leader in iPSC-derived clinical-grade cell products. In June 2021, it partnered with Neurophth Biotechnology to co-develop an iPSC-derived cell therapy to treat ocular diseases. Hopstem has a proprietary neural differentiation platform, a patented iPSC reprogramming method, and GMP manufactory and quality systems.
Some major disadvantages of iPSC are likely to hamper the market growth
The primary issue is the use of retroviruses to generate iPSCs as they are associated with cancer, and specifically, retroviruses can insert their DNA anywhere in the genome and subsequently trigger cancer-causing gene expression.
Moreover, in certain non-dividing cell types (such as PBMCs or elderly skin fibroblasts), the reprogramming rate of somatic cells to iPSCs is very low (less than 0.02 %). Thus, there is also a need to assess the quality and variability of the reprogramming process.
Segment Analysis
By Type
• Human iPSCs
• Mouse iPSCs
By Application
• Drug Development and Discovery
• Academic Research
• Toxicity Screening
Geographical Analysis
North America region holds the largest market share of global induced pluripotent stem cell (iPS Cell) market
North America holds the largest market in the global induced pluripotent stem cell (iPS Cell) market. Currently, the U.S. is the largest target market for pluripotent stem cell (PSC) technology, with more than 2,800 patent families filed. This accounts for more than 50% of the total patent families filed from 2006 to the present and significant market players established in this region. Increasing investments in research & development for product innovations and a positive outlook toward industrial livestock are expected to boost the regional market share. It is widely adopted as a lean meat replacement in North American countries, especially in the U.S. For instance, Semma Therapeutics, which Vertex Pharmaceuticals acquired for $950 million in late 2019, is developing a treatment for Type 1 diabetes. This treatment consists of cells derived from iPSCs that behave like pancreatic cells.
Competitive Landscape
The global induced pluripotent stem cell (ips cell) market is highly competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include Axol Bioscience Ltd, Cynata Therapeutics Limited, Evotec SE, FUJIFILM Cellular Dynamics, Inc, Ncardia, Pluricell Biotech, REPROCELL USA, Inc, Sumitomo Dainippon Pharma Co., Ltd, Takara Bio, Inc, Thermo Fisher Scientific, Inc, Shenzhen Haodi Huatuo Biotechnology Co., Ltd, Wuxi Yingnuui Biomedical Technology, Shanghai Haoran Biotechnology Co., Ltd, ScienCell Research Laboratories, Inc, Beijing Lebo Biotechnology Co., Ltd. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, Cynata Therapeutics manufacturers iPSC-derived MSCs using its proprietary Cymerus™ technology. In partnership with FUJIFILM Corporation, it is clinically testing these cells for the treatment of graft-versus-host disease (GvHD). It is also conducting trials for the treatment of critical limb ischemia (CLI), osteoarthritis (OA), and respiratory failure/distress, including ARDS.
Related Topic's
Muscle Stimulator Market, Gastroretentive Drug Delivery System Market, Penicillin Drug Market, Bovine Mastitis Market, Post-Polycythemia Vera Myelofibrosis Market
Induced pluripotent stem cells (iPS cell), immature cell generated from an adult (mature) cell and has regained the capacity to differentiate into any cell in the body. iPSCs can be used to explore the causes of disease onset and progression, create and test new drugs and therapies, and potentially treat previously incurable diseases.
Market Dynamics
The induced pluripotent stem cell (ips cell) market growth is driven by the increasing therapeutic advancements with iPS Cell, growing mergers and acquisitions of organizations to expand their portfolio in iPSCs, Increasing research activities are the major driving factors of the market.
Strong pipeline of iPSC is expected to drive the growth of global induced pluripotent stem cell (ips cell) market during the forecasting period.
The prevalence of chronic diseases worldwide is driving many vendors in the market to develop novel induced pluripotent stem cell therapies. Several drugs are in the late stages of clinical trials and are expected to receive marketing approvals over the forecast period. For instance, I Peace Inc. and Avery Therapeutics are collaborating to advance an iPSC-derived cell therapy for heart failure. I Peace is generating the GMP-grade iPSCs, while Avery Therapeutics is using them to manufacture its MyCardia. I Peace can mass production clinical-grade iPSC lines simultaneously in a single room using a miniaturized plate and robotic technology. Its facility is equipped with the fully-closed automated iPSC manufacturing system that meets the safety standards of the U.S. FDA and Japanese PMDA.
Hopstem Biotechnology is one of China's first iPSC cell therapy companies and a market leader in iPSC-derived clinical-grade cell products. In June 2021, it partnered with Neurophth Biotechnology to co-develop an iPSC-derived cell therapy to treat ocular diseases. Hopstem has a proprietary neural differentiation platform, a patented iPSC reprogramming method, and GMP manufactory and quality systems.
Some major disadvantages of iPSC are likely to hamper the market growth
The primary issue is the use of retroviruses to generate iPSCs as they are associated with cancer, and specifically, retroviruses can insert their DNA anywhere in the genome and subsequently trigger cancer-causing gene expression.
Moreover, in certain non-dividing cell types (such as PBMCs or elderly skin fibroblasts), the reprogramming rate of somatic cells to iPSCs is very low (less than 0.02 %). Thus, there is also a need to assess the quality and variability of the reprogramming process.
Segment Analysis
By Type
• Human iPSCs
• Mouse iPSCs
By Application
• Drug Development and Discovery
• Academic Research
• Toxicity Screening
Geographical Analysis
North America region holds the largest market share of global induced pluripotent stem cell (iPS Cell) market
North America holds the largest market in the global induced pluripotent stem cell (iPS Cell) market. Currently, the U.S. is the largest target market for pluripotent stem cell (PSC) technology, with more than 2,800 patent families filed. This accounts for more than 50% of the total patent families filed from 2006 to the present and significant market players established in this region. Increasing investments in research & development for product innovations and a positive outlook toward industrial livestock are expected to boost the regional market share. It is widely adopted as a lean meat replacement in North American countries, especially in the U.S. For instance, Semma Therapeutics, which Vertex Pharmaceuticals acquired for $950 million in late 2019, is developing a treatment for Type 1 diabetes. This treatment consists of cells derived from iPSCs that behave like pancreatic cells.
Competitive Landscape
The global induced pluripotent stem cell (ips cell) market is highly competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include Axol Bioscience Ltd, Cynata Therapeutics Limited, Evotec SE, FUJIFILM Cellular Dynamics, Inc, Ncardia, Pluricell Biotech, REPROCELL USA, Inc, Sumitomo Dainippon Pharma Co., Ltd, Takara Bio, Inc, Thermo Fisher Scientific, Inc, Shenzhen Haodi Huatuo Biotechnology Co., Ltd, Wuxi Yingnuui Biomedical Technology, Shanghai Haoran Biotechnology Co., Ltd, ScienCell Research Laboratories, Inc, Beijing Lebo Biotechnology Co., Ltd. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, Cynata Therapeutics manufacturers iPSC-derived MSCs using its proprietary Cymerus™ technology. In partnership with FUJIFILM Corporation, it is clinically testing these cells for the treatment of graft-versus-host disease (GvHD). It is also conducting trials for the treatment of critical limb ischemia (CLI), osteoarthritis (OA), and respiratory failure/distress, including ARDS.
Related Topic's
Muscle Stimulator Market, Gastroretentive Drug Delivery System Market, Penicillin Drug Market, Bovine Mastitis Market, Post-Polycythemia Vera Myelofibrosis Market
Contact Information:
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results